Irvine, Calif.-based Cell Vitals may have to rein in its claims for ReLuma skin-care products, touted as containing cell-signaling protein molecules derived from adult stem cells, following FDA’s Nov. 24 warning letter to the firm.
According to the agency, Cell Vitals’ products are unapproved drugs based on claims appearing on the company’s website, cellvitals.com, that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?